References

[1] World Health Organization. Availableonline:https://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf; jsessionid= CB10185391030DF727E80B7DC9747873?sequence=1 (accessed on 30 August 2019).

[2] European Society of Cardiology. Available online: https://www.escardio.org/Sub-specialty-communities/European- Association- of- Preventive-Cardiology-(EAPC)/News/global-statistics-on-diabetes (accessed on 30 August 2019).

[3] Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin.2017; 67(1): 7-30.

[4] Saftlas AF, Hoover RN, Brinton LA, et al. Mammographic densities and risk of breast cancer. Cancer. 1991; 67(11): 2833-2838.

[5] Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330:1304-1305 pmid:15849206.

[6] Mandelson, M.T.; Oestreicher, N.; Porter, P .L.; White, D.; Finder, C.A.; Taplin, S.H.;White, E. Breast density as a predictor of mammographic detection: Comparison of interval- and screen-detected cancers. J. Natl.Cancer Inst. 2000, 92, 1081-1087. [CrossRef] [PubMed].

[7] Boyd, N.F.; Guo, H.; Martin, L.J.; Sun, L.; Stone, J.; Fishell, E.; Jong, R.A.; Hislop, G.; Chiarelli, A.; Minkin, S.; et al. Mammographic density and the risk and detection of breast cancer. N. Engl. J. Med. 2007, 356, 227-236. [CrossRef] [PubMed]

[8] Elsebeth Lynge1, Ilse V ejborg, Zorana Andersen, My von Euler-Chelpin and George Napolitano. Mammographic Density and Screening Sensitivity,Breast Cancer Incidence and Associated Risk Factors in Danish Breast Cancer Screening. J. Clin. Med. 2019, 8, 2021; doi: 10.3390/jcm8112021.

[9] Corbellini A, Lugaro G, Giannattasio G, Torti G. Research on the antitumoral activity of the biguanides IV. Arch. Ital. Patol. Clin. Tumori 10(3), 197-210 (1967).

[10] Lev M Berstein, Dmitry A Vasilyev1, et al. Potential and real ‘antineoplastic’and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females. Future Oncol. (2015) 11(5), 759-770.

[11] Chen WW, Shao YY, Shau WY, Lin ZZ, Lu YS, Chen HM, et al. The impact of diabetes mellitus on prognosis of early breast cancer in Asia. Oncologist. 2012; 17: 485-91. 

[12] Bowker SL, Richardson K, Marra CA, Johnson JA. Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women. Diabetes Care. 2011; 34: 2542-4. 

[13] Kaplan MA, Pekkolay Z, Kucukoner M, Inal A, Urakci Z, Ertugrul H, et al. Type 2 diabetes mellitus and prognosis in early stage breast cancer women. Med Oncol. 2012; 29: 1576-80. 

[14] Redaniel MT, Jeffreys M, May MT, Ben-Shlomo Y, Martin RM. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control. 2012; 23: 1785-95.

[15] Karsten Buschard1 • Katrin Thomassen2 • Elsebeth Lynge2 • Ilse Vejborg3 • Anne Tjønneland4 • My von Euler-Chelpin2 • Zorana Jovanovic Andersen2. Cancer Causes Control, (2017), 28: 13-21.

[16] Libby, G., L.A. Donnelly, P .T. Donnan, et al. (2009). New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 32: 1620-1625.

[17] Bodmer, M., C. Meier, S. Krahenbuhl, et al. (2010). Longterm metformin use is associated with decreased risk of breast cancer. Diabetes Care 33: 1304-1308.

[18] Yang, X., W.Y. So, R.C. Ma, et al. (2011). Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 34: 375-380.

[19] Donadon, V., M. Balbi, F. Valent & A. Avogaro. (2010). Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J. Gastroenterol. 16: 3025-3032.

[20] Buchs, A.E. & B.G. Silverman. (2011). Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study. Metabolism. 60: 1379-1385

[21] Decensi, A., M. Puntoni, P. Goodwin, et al. (2010). Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev. Res. (Phila) 3: 1451-1461.

[22] Evans, J.M., L.A. Donnelly, A.M. Emslie-Smith, et al. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305.

[23] Landman, G.W., N. Kleefstra, K.J. van Hateren, et al. (2010). Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33: 322-326.

[24] He, X.X., S.M. Tu, M.H. Lee & S.C. Y eung. (2011). Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann. Oncol. [Epub ahead of Print]. doi:10.1093/annonc/mdr020. 

[25] Baur, D.M., J. Klotsche, O.P. Hamnvik, et al. (2010). Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism. 60: 1363-1371.

[26] Bodmer, M., C. Meier, S. Krahenbuhl, S. S. Jick, and C. R. Meier. (2010). Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33:1304-1308.

[27] Bosco, J. L., S. Antonsen, H. T. Sorensen, L. Pedersen, and T. L. Lash. (2011). Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol. Biomarkers Prev. 20: 101-111.

[28] Chlebowski, R. T., A. McTiernan, J. Wactawski-Wende, J. E. Manson, A. K. Aragaki, T. Rohan, et al. (2012). Diabetes, metformin, and breast cancer in postmenopausal women. J. Clin. Oncol. 30: 2844-2852.

[29] Ruiter, R., L. E. Visser, M. P. van Herk-Sukel, J. W. Coebergh, H. R. Haak, P. H. Geelhoed-Duijvestijn, et al. (2012). Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large popula-tion-based follow-up study. Diabetes Care, 35:119-124.

[30] Redaniel, M. T., M. Jeffreys, M. T. May, Y. Ben-Shlomo, and R. M. Martin. (2012). Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control 23: 1785-1795.

[31] Currie, C. J., C. D. Poole, and E. A. Gale. (2009). The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766-1777.

[32] Libby, G., L. A. Donnelly, P. T. Donnan, D. R. Alessi, A. D. Morris, and J. M. Evans. (2009). New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625.

[33] Morden, N. E., S. K. Liu, J. Smith, T. A. Mackenzie, J. Skinner, and M. Korc. (2011). Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 34: 1965-1971.

[34] Zhang, P., H. Li, X. Tan, L. Chen, and S. Wang. (2013). Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 37: 207-218.

[35] Bridget A. Oppong, Lindsay A. Pharmer, Sabine Oskar, Anne Eaton, Michelle Stempel, Sujata Patil, & Tari A. King. The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Medicine 2014; 3(4): 1025–1034.

[36] Chlebowski RT, McTiernan A, Wactawski-Wende J, et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 30:2844-2852, 2012.

[37] Sara Gandini, Matteo Puntoni, Brandy M. Heckman-Stoddard, Barbara K. Dunn, Leslie Ford, Andrea DeCensi, and Eva Szabo. Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders. American Association for Cancer Research. First July 1, 2014; DOI: 10.1158/1940-6207.CAPR-13-0424.

[38] Muszyńska-Ogłaza A, Zarzycka-Lindner G, Olejniczak H, Polaszewska-Muszyńska M, Junik R.Endokrynol Pol. Use of met-formin is associated with lower incidence of cancer in patients with type 2 diabetes.2017;68(6):652-658. doi: 10.5603/EP.a2017.0054. Epub 2017 Oct 12.

[39] Erica J. Lee Argov, Teofilia Acheampong, Mary Beth Terry, Carmen B. Rodriguez, Mariangela Agovino, Ying Wei, Shweta Athilat and Parisa Tehranifar. Lee Argov. Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density. Breast Cancer Research (2020) 22: 99.

[40] Monica Franciosi, Giuseppe Lucisano, et al. Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review. PLoS ONE 8(8): e71583. doi:10.1371/journal.pone.0071583.

[41] Jin-Liern Hong, Michele Jonsson Funk, John B. Buse, Louise M. Henderson, Jennifer L. Lund, Virginia Pate, and Til Stürmer. Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. Epidemiology 2017; 28: 446-454.

[42] H. Qiu1, G. G. Rhoads, J. A. Berlin, S. W. Marcella, & K. Demissie. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 15: 349–357, 2013.

[43] Rachel Dankner, Nirit Agay, Liraz Olmer, Havi Murad, Lital Keinan Boker, Ran D. Balicer, and Laurence S. Freedman. Met-formin Treatment and Cancer Risk: Cox Regression Analysis, With Time Dependent Covariates, of 320,000 Persons With In-cident Diabetes Mellitus. Am J Epidemiol. 2019; 188(10): 1794–1800.

[44] Jiralerspong S, Palla SL, Giordano SH et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breastcancer. JClinOncol 2009; 27: 3297–3302.

[45] Hong Xu et al. Metformin Use Is Associated With Better Survival of Breast Cancer Patients With Diabetes: A Meta-Analysis. The Oncologist 2015; 20: 1236–1244.

[46] Bridget A. Oppong, Lindsay A. Pharmer, Sabine Oskar, Anne Eaton, Michelle Stempel, Sujata Patil & Tari A. King. The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Medicine 2014; 3(4): 1025–1034.

[47] Bayraktar, S., L. F. Hernadez-Aya, X. Lei, F. Meric-Bernstam, J. K. Litton, L. Hsu, et al. (2012). Effect of metformin on survival outcomes in diabetic patients with triple.

[48] He, X., F. J. Esteva, J. Ensor, G. N. Hortobagyi, M. H. Lee, and S. C. Yeung. (2012). Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann. Oncol., 23:1771–1780.

[49] Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA, Jr., Fumagalli D, Sarp S, et al. (2017). Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast cancer: analysis from the ALTTO phase III randomized trial. J Clin Oncol. 2017; 35(13):1421-1429.

[50] Jiralerspong S, Palla SL, Giordano SH et al. (2009). Metformin and pathologic complete response to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297–3302

[51] DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, et al. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat. 2014; 148(1): 81-90.

[52] Goldvaser H, et al. The association between treatment for metabolic disorders and breast cancer characteristics. Int J Endocrinol. 2016; 2016:4658469.

[53] Serena Tharakan, et al. Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients. Oncology. March 17, 2020. DOI: 10.1159/000506076.

[54] Bayraktar, S., Hernadez-Aya, et al. (2012). Effect of metformin on survival outcomes in diabetic patients with triple recep-tor-negative breast cancer. Cancer, 118, 1202-1211.

[55] Jacob, L., et al., Impact of metformin on metastases in patients with breast cancer and type 2 diabetes, Journal of Diabetes and Its Complications (2016), http://dx.doi.org/10.1016/j.jdiacomp.2016.04.003.

[56] Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA, Jr., Fumagalli D, Sarp S, et al. Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast cancer: analysis from the ALTTO phase III randomized trial. J Clin Oncol. 2017; 35(13): 1421-1429.

[57] Chen TW, Liang YN, Feng D, Tao LY, Qi K, Zhang HY, Wang HX, et al. Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90. J BUON. 2013; 18(1):51-56.

[58] V azquez-Martin A, Oliveras-Ferraros C, Cufi S, Del Barco S, Martin-Castillo B, Lopez-Bonet E, Menendez JA. The an-ti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncol Rep. 2011; 25(1):135-140.

[59] Lega, I. C., P. C. Austin, A. Gruneir, P. J. Goodwin, P. A. Rochon, and L. L. Lipscombe. 2013. Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 36:3018–3026.

[60] Lev M Berstein, Dmitry A Vasilyev1, et al. Potential and real ‘antineoplastic’ and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females. Future Oncol. (2015) 11(5), 759–770.

[61] Friedl P and Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-374.

[62] Sahai E. Illuminating the metastatic process. Nat Rev Cancer 2007; 7: 737-749.

[63] Clark AG and Vignjevic DM. Modes of cancer cell invasion and the role of the microenvironment. Curr Opin Cell Biol 2015; 36: 13-22.

[64] Friedl P and Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011; 147: 992-1009.

[65] Schulten H-J. Pleiotropic effects of metformin on cancer. Int J Mol Sci. 2018; 19(10):2850.

[66] Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N. & Pollak, M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269–10273 (2006).

[67] Alimova, I. N., B. Liu, Z. Fan, S. M. Edgerton, T. Dillon, E. Lind, et al. (2009). Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8:909–915.

[68] Zakikhani, M., R. Dowling, I. G. Fantus, N. Sonenberg, and M. Pollak. (2006). Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66:10269–10273.

[69] Dowling, R. J., M. Zakikhani, I. G. Fantus, M. Pollak, and N. Sonenberg. (2007). Metformin inhibits mammalian target of ra-pamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67:10804–10812.

[70] Joseph Zhou, Scott Massey, Darren Story and Lixin Li. Metformin: An Old Drug with New Applications.Int. J. Mol. Sci. 2018, 19, 2863; doi:10.3390.

[71] Zheng G, Shen Z, Xu A, Jiang K, Wu P, Yang X, Chen X and Shao J. Synergistic chemopreventive and therapeutic effects of Co-drug UA-Met: implication in tumor metastasis. J Agric Food Chem 2017; 65: 10973-10983.

[72] Simon R. Lord, Jennifer M. Collins, Wei-Chen Cheng, et al. Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. British Journal of Cancer (2020) 122:258–265.

[73] Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F. et al. Systemic treatment with the antidia-betic drug metformin selectively impairs p53deficient tumor cell growth. Cancer Res. 67, 6745–6752 (2007). 

[74] Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J. et al. Role of AMPactivated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174 (2001). 

[75] Saeedi, R., Parsons, H. L., Wambolt, R. B., Paulson, K., Sharma, V., Dyck, J. R. et al. Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms. Am. J. Physiol. Heart Circ. Physiol. 294, H2497–H2506 (2008). 

[76] Cool, B., Zinker, B., Chiou, W., Kifle, L., Cao, N., Perham, M. et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell. Metab. 3, 403–416 (2006).

[77] Zang, M., Zuccollo, A., Hou, X., Nagata, D., Walsh, K., Herscovitz, H. et al. AMPactivated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem. 279, 47898–47905 (2004).

[78] Lord, S. R., Cheng, W. C., Liu, D., Gaude, E., Haider, S., Metcalf, T. et al. Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer. Cell Metab. 28, 679–688 e674 (2018). 

[79] Liu, X., Romero, I. L., Litchfield, L. M., Lengyel, E. & Locasale, J. W. Metformin targets central carbon metabolism and reveals mitochondrial requirements in human cancers. Cell Metab. 24, 728–739 (2016).

[80] Wheaton, W.W., Weinberg, S.E., Hamanaka, R.B., Soberanes, S., Sullivan, L.B., Anso, E., Glasauer, A., Dufour, E., Mutlu, G.M., Budigner, G.S., et al. (2014). Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife 3, e02242.

[81] Del Barco S, V azquez-Martin A, Cufi S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B, et al. Metformin: multi-faceted protection against cancer. Oncotarget. 2011; 2(12):896-917.

[82] Rice S, Pellatt L, Ramanathan K, Whitehead SA, Mason HD. Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway. Endocrinology. 2009; 150(10):4794-4801.

[83] Brown KA, Hunger NI, Docanto M, Simpson ER. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat. 2010; 123(2):591596.

[84] Takemura Y, Osuga Y, Yoshino O, Hasegawa A, Hirata T, Hirota Y, Nose E, et al. Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. J Clin Endocrinol Metab. 2007; 92(8): 3213-3218.

[85] Queiroz EA, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, Barbosa AM, et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One. 2014; 9(5):e98207.

[86] Amaral MEA, Nery LR, Leite CE, de Azevedo Junior WF, Campos MM. Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. Invest New Drugs. 2018; 36(5):782-796.

[87] Turacli I D, Umudum H, Pampal A, Candar T, Kavasoglu L, Sari Y. Do MCF-7 cells cope with metformin treatment under energetic stress in low glucose conditions? Molecular Biology Reports. 2018; 45(3):195-201.

[88] Berstein LM. Metformin, insulin, breast cancer and more. Future Oncol. 2009; 5(3):309-312.

[89] Berstein LM, Boyarkina MP, Tsyrlina EV, Turkevich EA, Semiglazov VF. More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. Med Oncol. 2011; 28(4): 1260-1263.

[90] Hardy KM, Booth BW, Hendrix MJ, Salomon DS, Strizzi L. ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia. 2010; 15(2): 191-199.

[91] Zhang J, Li G, Chen Y, Fang L, Guan C, Bai F, Ma M, Lyu J and Meng QH. Metformin inhibits tumorigenesis and tumor growth of breast cancer cells by upregulating miR-200c but downregulating AKT2 expression. J Cancer 2017; 8: 1849-1864.

[92] Gerstein HC, Pare G, Hess S, et al. (2017). Growth differentiation factor 15 as a novel biomarker for metformin. Diabetes Care 40(2): 280–283.

[93] Shiu Lun Au Yeung, Shan Luo, Mary Schooling, et al. The impact of GDF-15, a biomarker for metformin, on the risk of coro-nary artery disease, breast and colorectal cancer, and type 2diabetes and metabolic traits: a Mendelian randomisation study. Diabetologia (2019) 62:1638–1646.

[94] Taddei S, Virdis A. (2010). Growth differentiation factor-15 and cardiovascular dysfunction and disease: malefactor or innocent by stander? Eur Heart J 31(10):1168–1171.

[95] Li C, Wang X, Casal I et al. (2016). Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer. J Cell Mol Med 20(8):1420–1426.

[96] Schexnayder C, Broussard K, Onuaguluchi D, Poche A, Ismail M, McAtee L, Llopis S, Keizerweerd A, McFerrin H and Wil-liams C. Metformin Inhibits Migration and Invasion by Suppressing ROS Production and COX2 Expression in MDAMB-231 Breast Cancer Cells. Int J Mol Sci 2018; 19: 3692.

[97] Yong Chang Chen, He Li, Jing Wang. Mechanisms of metformin inhibiting cancer invasion and migration. Am J Transl Res 2020;12(9): 4885-4901.

[98] Liu, B., Z. Fan, S. M. Edgerton, X. Yang, S. E. Lind, and A. D. Thor. (2011). Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle 10:2959–2966.

[99] Scherbakov AM, Sorokin DV, Tatarskiy VV, Jr., Prokhorov NS, Semina SE, Berstein LM, Krasil'nikov MA. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling. IUBMB Life. 2016; 68(4): 281-292.

[100] Ma J, Guo Y , Chen S, Zhong C, Xue Y, Zhang Y, Lai X, et al. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC Cancer. 2014; 14: 172.